Q-omics provides the consensus-scored ZNF354C profile across patient tissues and cancer cell-line models. ZNF354C expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF354C is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZNF354C RNA expression shows 19,964 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where ZNF354C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF354C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF354C survival associations across molecular data types. ZNF354C RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF354C RNA expression–survival associations across cancer types. High ZNF354C expression shows unfavorable associations in UCEC and LUSC, but favorable associations in KIRC, HNSC, LUAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF354C RNA expression.
This table summarizes ZNF354C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF354C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF354C shows lower tumor expression in THCA, KICH, UCEC, BRCA, COAD and LUAD. The THCA box plot shows higher ZNF354C RNA expression in normal versus tumor tissue (log2 FC = −0.987, t-test p < 0.001).
This table shows molecular features associated with ZNF354C in patient tissues and cancer cell lines. In patient samples, ZNF354C shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF354C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
